Key to this session will be addressing business needs across the lifecycle, whereby participants will:
• Develop an in-depth understanding of how a diverse range of facilitated activities (Rapid Immersion, Threat Assessment and Competitor Simulations) can help deliver strategic and competitive insights within an organization
• Appreciate the importance of leveraging the outcomes of workshops to inform and direct decision making
• Receive hands-on opportunities to apply learnings to a pharma case-study in a learning environment
Using business case studies, real-life experiences and validated theory, the INOVIS team will equip you with a number of go-to techniques that can be rapidly integrated into ongoing CI Practice, whether you’re a seasoned CI professional veteran, or newer to the field.
Many biopharma CI reports disseminated by the Agency are overly verbose, high-level and lack the substantive actionability required for internal usage – facilitating a seamless cascade to management & leadership.
Today’s workshop will translate classical stylistic business writing techniques including those of Strunk and White to the 21st-century biopharmaceutical CI and Strategy world.
In this workshop, we will facilitate two (2) breakouts during which “raw intelligence learnings” will be synthesized and translated into actionable CI deliverables using PowerPoint writing skills and infographic design techniques.
This Workshop is facilitated by David Alderman, President of Molekule Consulting, a global competitive intelligence and strategy consultancy dedicated to the life sciences and biopharmaceutical verticals. David has deep experience from early-development to late-lifecycle management and beyond within biopharma across the competitive landscape among myriad therapy areas, players and subject matters. David is a Subject Matter Expert on the biopharmaceutical vertical; with a particular focus on competition within branded biopharma, small molecule generics and biosimilars.
We call this ecosystem the DrugOme™. The DrugOme™, supports analyses for the strategic decisions of many groups in a therapeutic area agnostic way across all phases of drug development, from discovery through commercialization. We discuss the challenges involved in translating technology-driven insight into action across many groups in many companies and across all phases of drug development.
Topics we will cover:
• What are the 10 “commandments” to build a successful CI team
• What is needed to make the CI team relevant and impactful for a company
• How to recruit the best CI talent into the department and retain them
The audience can expect to be able to participate actively in the “conversation” and contribute to the program.
Launching a new product is exciting and intense, but transitioning a product from launch to growth requires endurance and deliberation. Furthermore, scaling requires leaders who understand the role of competitive intelligence and how to manage the increased organizational and business complexity of growth.
Having supported numerous blockbuster brands, we have identified three frameworks to help brand leaders achieve high growth. The frameworks are:
• Leading high growth
• Competitive Prioritization Assessment
• Competitive readiness
In this talk, we will introduce the three frameworks. Additionally, we will share how the CI professional can have a greater impact on high-growth brands by shifting focus from strategy to execution.
Presentation attendees will receive a copy of the article “Leading High Growth Ventures” from Harvard Business Publishing. We look forward to seeing you there!
Over the last several years, pharmaceutical companies have embraced social media as a marketing, messaging, and brand awareness tool to reach both patients and physicians. Beyond company driven content, evangelists / KOLs, and the public at large can also contribute to the conversation on products, brands, and opinions that may impact patient / physician sentiment or adoption of a new drug. As a result, social media platforms offer a significant amount of secondary intelligence that can be leveraged to better understand company and product strategies.
In 2014 Dig Worldwide developed and introduced COGIntel a quick, robust and cost effective COGs benchmarking solution.
Technical Cost Modelling (TCM) , a method developed at MIT in the 1980’s has long been the gold standard in benchmarking cost-of-goods sold which is time and resource intensive with a limited shelf-life. Although not as precise as TCM, Dig Worldwide’s bespoke COGIntel method allows rapid and cost effective COG benchmarking analysis that provides “good enough” competitive intelligence for strategic decision making. Performance gaps and areas of advantage or disadvantage become visible verses forgotten.
An illustrative CAR-T case study will form an integral part of the talk to help illustrate Dig Worldwide’s methodology.
• Information management from public domain: sifting through the ‘noise’
• Using the hybrid of technology and human touch to create successful outcomes
• Case study: ASCO2021
From target identification and drug development to patient diagnosis and even to patient care, CI professionals need to be able to keep up with the increasing pace of business and ever-expanding competitive landscape. Through advancements in research, CI professionals can better understand the vast amount of patient, research, and diagnostic data to make better investment decisions.
Join this session to learn:
• How to leverage the building blocks of Natural Language Processing and Machine learning to drive forward offerings in Sentiment Analysis, thematic and KPI extraction, and enterprise knowledge management
• How these technologies are already impacting the pharma professional’s day-to-day
• How advancements in AI will impact the pharma industry long term and may reshape the duties of a Competitive Intelligence team
Specifically this presentation will enable you to:
• Advance your understanding of core Gx/biosimilar market dynamics and corresponding CI solutions
• Set up a best-in-industry Gx/biosimilar regulatory intelligence (RI) and CI tracking program
• Understand Gx / biosimilar product development and entry strategies
Given “price” is one of the four P’s of marketing along with product, place and promotion it is essential to include this component into integrated monitoring in order to make fully informed strategic and tactical decisions. While understanding market access intelligence is critical in markets with multiple competitors such as diabetes, respiratory ailments and multiple sclerosis, it is of increasing importance in oncology, biosimilars, mature brands and even rare disease spaces.
In this presentation we will discuss:
• What is market access intelligence?
• Reasons why market access intelligence is often not fully investigated
• The impact of FDAMA 114 passage on drug and device manufacturer communications with payers, formulary committees and similar entities
• Examples of market access intelligence such as
o Rebating, price protection and other terms negotiated by payers
o Value based agreements
o Clinical and economic messaging to payers
• Use of organizational benchmarking for market access account teams, field reimbursement managers, HEOR teams and patient assistance program support personnel
• How leveraging national provider identification numbers can enhance intelligence collection and benchmarking for competitor patient support services
• Use of near real-time claims adjudication to deliver insights
These paths present the changes that must occur for an event to happen, which can then drive competitor and market monitoring. The session will explore how to build an indicator pathway, identify key events along the pathway, and determine specific responses to events. Making the most of the scenario planning results and the indicator pathways also includes building a monitoring system to alert when an indicator event is about to happen and a response for when that event happens. The session will cover processes used to identify what indicators should be monitored, how to monitor, the importance of adjustability within the monitoring program, and how to prepare fast response for when the event occurs
o Technology is also enabling democratization of data and insights through self-service and collaboration platforms, thus enabling CI teams to provide more impact.
• What are the opportunities for the CI function in such a dynamic market? How can these opportunities be realized?
• What can CI functions and managers do to ensure their intelligence continues to drive value, growth, and strategy?
• Use of masks required: Please bring your own if preferred, but masks and hand sanitizer will also be provided.
• Greetings should be socially distanced: no handshakes, hugs, or kisses, etc.
• Meeting space will accommodate more spacing between attendees.
• The hotel experience will be entirely revamped with specific cleaning protocols.